RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $60

Benzinga · 2d ago
RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $85 to $60.